News Sentiment

VRDN sentiment intelligence

Viridian Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 19.74 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+1.8% over one week, +20.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN)

Market Reaction

Balanced read

68/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 1.8% Price digesting
Trend fit Trend inactive 20.7% over four weeks
Fair value 4.0% Near fair-value range
Market Dynamics buy signal

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 37
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 15
Stock Titan 8
TradingView 7
simplywall.st 4
Simply Wall Street 3
MT Newswires 3
Moomoo 2
AD HOC NEWS 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 14
Regulatory and legal 9
Analyst action 5
Deals and strategy 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 63
Market source Direct company coverage

Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value Today

Viridian Therapeutics (VRDN) stock has dropped 37.8% year-to-date, but despite this decline, valuation checks suggest it remains expensive, trading at a high P/S ratio of 29.7x compared to industry averages. The tailored Fair Ratio further indicates overvaluation, although this c

Tone
Negative 36/100
Event
Market update
Published
15 Jul 2026 12:11
Source
Market source
TradingView Direct company coverage

VRDN6389238 Bond Coupon Profile — Rate & Payments

This article provides key details about the Viridian Therapeutics, Inc. VRDN6389238 bond. It highlights the current coupon rate of 1.75% and indicates that the next interest payment is scheduled for November 16, 2026. The piece also notes that further in-depth coupon data and an

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 04:11
Source
TradingView
TradingView Direct company coverage

VRDN6389238 Bond Profile — Key Metrics

This article provides key metrics for the Viridian Therapeutics, Inc. bond, VRDN6389238, which has a 1.75% coupon and matures on May 15, 2032. It details the issuer's profile as a biopharmaceutical company focused on autoimmune and rare diseases. The bond has an outstanding amoun

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 16:11
Source
TradingView
Moomoo Direct company coverage

Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $43

Wedbush analyst Laura Chico has reiterated a Buy rating for Viridian Therapeutics (VRDN.US) and maintained a target price of $43. According to TipRanks data, Chico demonstrates a 53.7% success rate and a 14.6% average return over the past year, indicating a positive track record

Tone
Positive 74/100
Event
Analyst action
Published
14 Jul 2026 14:11
Source
Moomoo
Simply Wall Street Direct company coverage

Viridian Therapeutics (VRDN) Could Be 87% Below Fair Value After FDA Approval

Viridian Therapeutics (VRDN) recently received FDA approval for Lumvoa, its first commercial product, which has positively impacted its stock performance with significant short-term gains. Despite a high Price-to-Sales ratio of 31.5x, suggesting overvaluation compared to industry

Tone
Positive 66/100
Event
Regulatory and legal
Published
10 Jul 2026 23:41
Source
Simply Wall Street
TradingView Direct company coverage

Total debt per share of Viridian Therapeutics, Inc. – HAM:1S1

This article provides financial data for Viridian Therapeutics, Inc. (HAM:1S1), specifically focusing on its total debt per share. It presents the period, value, and change percentages related to this metric, indicating what appears to be part of a financial report or overview.

Tone
Neutral 50/100
Event
Balance sheet
Published
10 Jul 2026 12:10
Source
TradingView
TradingView Direct company coverage

Total assets of Viridian Therapeutics, Inc. – HAM:1S1

The article focuses on the total assets of Viridian Therapeutics, Inc., identifiable by its Hamburg Stock Exchange ticker 1S1. It appears to be a stub or financial data page rather than a detailed news article, providing context within TradingView's platform. The content primaril

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 11:40
Source
TradingView
TradingView Direct company coverage

Tangible book value per share of Viridian Therapeutics, Inc. – HAM:1S1

The article provides financial information for Viridian Therapeutics, Inc. (HAM:1S1), specifically focusing on its tangible book value per share. It appears to be a financial data snippet from TradingView, indicating the market is currently closed with no trades recorded.

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 19:05
Source
TradingView
AD HOC NEWS Direct company coverage

Viridian Therapeutics outlines eye disease strategy as Nasdaq-listed biotech builds its pipeline

Viridian Therapeutics, a Nasdaq-listed biotech, is focused on developing antibody-based treatments for thyroid eye disease and similar autoimmune conditions affecting the eye. The company aims to expand its pipeline and collaborate with manufacturing partners to achieve long-term

Tone
Positive 72/100
Event
Market update
Published
08 Jul 2026 15:39
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

Viridian Therapeutics updates pipeline plans as thyroid eye disease program advances

Viridian Therapeutics (VRDN) is a clinical-stage biotechnology company focusing on autoimmune and rare diseases, particularly advancing its pipeline strategy for thyroid eye disease. The company's lead monoclonal antibody program targets specific immune pathways for this conditio

Tone
Positive 73/100
Event
Market update
Published
07 Jul 2026 21:57
Source
AD HOC NEWS
Sahm Direct company coverage

The Bull Case For Viridian Therapeutics (VRDN) Could Change Following FDA Approval Of Lumvoa For Thyroid Eye Disease

Viridian Therapeutics recently received FDA approval for Lumvoa (veligrotug-vvze) for both active and chronic thyroid eye disease, marking its first commercial product and a significant shift in its investment narrative. The company now faces the challenge of converting this appr

Tone
Positive 71/100
Event
Regulatory and legal
Published
06 Jul 2026 10:10
Source
Sahm
Finviz Direct company coverage

VRDN - Viridian Therapeutics Inc Earnings

This article provides a detailed financial overview of Viridian Therapeutics Inc (VRDN), including its last closing price, market capitalization, income, sales, and various financial ratios. It also presents earnings per share (EPS) forecasts, insider and institutional ownership

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 00:09
Source
Finviz
Stock Titan Direct company coverage

If You Invested $1,000 in Viridian Therapeutics Inc (VRDN)

This article analyzes hypothetical investments in Viridian Therapeutics Inc (VRDN), detailing the returns of $1,000 invested over 1, 5, and 10 years, and comparing its performance to the S&P 500. It also provides an in-depth company profile, outlining Viridian's focus on developi

Tone
Positive 62/100
Event
Market update
Published
04 Jul 2026 08:40
Source
Stock Titan
Market source Direct company coverage

VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know

Shares of Viridian Therapeutics (VRDN) rose 6.3% last week following FDA approval for veligrotug (brand name Lumvoa) for thyroid eye disease (TED), marking the company's entry into the commercial biotechnology sector. Lumvoa is the first FDA-approved TED therapy with labeling for

Tone
Positive 73/100
Event
Regulatory and legal
Published
01 Jul 2026 14:41
Source
Market source
Medical Marketing and Media Direct company coverage

Rx Rundown: Zymeworks, Viridian Therapeutics, BioCryst and more

This edition of Rx Rundown covers significant news in the medical marketing and pharmaceutical industry. Key highlights include Zymeworks acquiring Theravance Biopharma, several FDA approvals and rejections for new and existing drugs, and substantial funding rounds for various bi

Tone
Positive 71/100
Event
Market update
Published
01 Jul 2026 11:39
Source
Medical Marketing and Media
Finviz Direct company coverage

VRDN - Viridian Therapeutics Inc Options

This page provides a detailed financial overview of Viridian Therapeutics Inc (VRDN), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics, insider ownership, institutional ownership, and short

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 08:10
Source
Finviz
Simply Wall Street Direct company coverage

Viridian Therapeutics (VRDN) Wins FDA Approval For Lumvoa, Is The Upside Already Priced In?

Viridian Therapeutics (VRDN) recently received FDA approval for Lumvoa, its treatment for thyroid eye disease, leading to a 6% after-hours stock increase. Despite a 40.11% year-to-date drop, the stock shows a 26.99% one-year return, prompting questions about its current valuation

Tone
Neutral 50/100
Event
Regulatory and legal
Published
01 Jul 2026 07:10
Source
Simply Wall Street
Eyes On Eyecare Direct company coverage

FDA clears Viridian's veligrotug for TED as Lumvoa

Viridian Therapeutics has received FDA approval for Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED), marking it as the second FDA-approved treatment for the condition. Lumvoa is an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in

Tone
Positive 94/100
Event
Regulatory and legal
Published
30 Jun 2026 18:53
Source
Eyes On Eyecare
VisionMonday.com Direct company coverage

Viridian Therapeutics Receives FDA Approval for Lumvoa for the Treatment of Thyroid Eye Disease (TED)

Viridian Therapeutics announced that the FDA has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED), following priority review and support from the THRIVE and THRIVE-2 clinical trials. The company plans an immediate launch and has established Viridia

Tone
Positive 95/100
Event
Regulatory and legal
Published
30 Jun 2026 04:10
Source
VisionMonday.com